The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas, where the company has a leading position, with high-quality products that are innovative or unique in the market.
This acquisition will enhance Lupin's Respiratory business in Germany, by aiding in the expansion of the newly established franchise, following the introduction of Luforbec™.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content